<DOC>
	<DOC>NCT01558505</DOC>
	<brief_summary>Drug-eluting balloon showed positive results in terms of restenosis reduction in peripheral intervention (PTA). The aim of the study is to investigate in a randomized fashion the efficacy and safety of Paclitaxel-eluting balloon (PEB) (In.Pact Amphirion, Invatec, Brescia, Italy) versus non drug-eluting balloon (NEB) (Amphirion deep, Invatec, Brescia, Italy) in diabetic patients with Critical Limb Ischemia (CLI) undergoing PTA of below-the-knee (BTK) vessels.</brief_summary>
	<brief_title>Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<criteria>age&gt;18 years angiographic stenosis&gt;50% or occlusion of one belowknee vessel allergy to Paclitaxel contraindication for combined antiplatelet treatment life expectancy &lt;1 year hypersensitivity or contraindication to one of the study drugs lack of consent need for amputation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>critical limb ischemia</keyword>
	<keyword>drug-eluting balloon</keyword>
	<keyword>restenosis</keyword>
</DOC>